TRDA Kronos AI forecast
A 30-trading-day price forecast for Entrada Therapeutics Inc. (TRDA) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Entrada Therapeutics Inc. at $6.92 on 2026-12-08, +56.9% from the last close of $4.41 on 2026-10-27. Eight out of ten sampled paths end between $6.73 and $7.23, and 8 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of TRDA
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $4.48 | $4.22 | $4.90 |
| 2026-11-10 | $6.08 | $5.48 | $6.71 |
| 2026-11-17 | $6.85 | $6.56 | $7.06 |
| 2026-11-24 | $6.81 | $6.40 | $7.57 |
| 2026-12-01 | $6.99 | $6.76 | $7.36 |
| 2026-12-08 | $6.92 | $6.73 | $7.23 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for TRDA?
- Kronos AI's median forecast for TRDA is $6.92 in 30 trading days, +56.9% from the last close, with a 10–90% range of $6.73 to $7.23.
- Is the TRDA Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- LLY — Eli Lilly and Company
- JNJ — Johnson & Johnson
- ABBV — AbbVie Inc.
- MRK — Merck & Company Inc.
- NVS — Novartis AG
- AZN — AstraZeneca PLC